The role of prognostic markers (MiB-1, RB and bcl-2) in the diagnosis of parathyroid tumors

Modern Pathology

Volumn 10, Issue 1, 1997, Pages 12-17

  Vargas, M P ^a   Vargas, H I ^a   Kleiner, D E ^a   Merino, Maria J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

bcl 2; MiB 1; p53; parathyroid adenoma; parathyroid carcinoma; retinoblastoma

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PARATHYROID NEOPLASMS; PRECANCEROUS CONDITIONS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031040919     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. DeLellis RA. Tumors of the parathyroid glands. In: Rosai J, Sobin LH, editors. Atlas of tumor pathology. 3rd series. Fascicle 6. Washington, DC: Armed Forces Institute of Pathology, 1993: 53-63.
2. Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973;31:600-5.
3. Evans H. Pathologic diagnosis of parathyroid carcinoma. Int J Surg Pathol 1993;1:139-42.
4. Levin K. Deoxyribonucleic acid cytometry helps identified parathyroid carcinomas. J Clin Endocrinol Metab 1988;67: 779-84.
5. Abbona G, Papotti M, Gasparri G, Bussolati G. Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol 1995;26:135-8.
6. Cryns V, Thor A, Xu H, Hu SX, Wierman ME, Vickery AL Jr, et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994;330:757-61.
7. Cryns V, Rubio M, Thor A, Louis DN, Arnold A. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 1994;78:1320-24.
8. Lloyd R, Carney J, Ferreiro J, Jin L, Thompson G, van Heerden J, et al. Immunohistochemical analysis of the cell cycle-associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas. Endocr Pathol 1995; 6:279-87.
9. Tsujimoto Y, Cossman J, Jaffe E. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228:1440-3.
10. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA. bcl-2 expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994;172:337-42.
11. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54:2095-7.
12. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, et al. bcl-2 protein in non-small cell lung carcinomas. N Engl J Med 1993;329:690-4.
13. Saegusa M, Takano Y, Okayasu I. bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol 1995;121: 357-63.
14. Bondenson L, Sandelin K, Grimelius L. Histopathologic variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 1993;17:820-9.
15. Snover D, Foucar K. Mitotic activity in benign parathyroid diseases. Am J Clin Pathol 1981;75:345-7.
16. Rattner C, Marrone G, Kasdon E, Silen W. Recurrent hyperparathyroidism due to implantation of parathyroid tissue. Am J Surg 1985;149:745-8.
17. Benedict W, Xu H, Hu S, Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 1990;85:988-93.
18. DeLellis R. Does the evaluation of proliferative activity predict malignancy or prognosis in endocrine tumors? Hum Pathol 1995; 26:131-4.
19. 1 cells: correlation to changes in total protein level. Oncogene 1991;6:1139-46.
20. Levine A, Momand J, Finlay C. The p53 tumour suppressor gene. Nature 1991;351:453-6.
21. Nigro J, Baker S, Preisinger A, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
22. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991;253:49-53.
23. Wynford-Thornas D. p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 1992;166:239-330.
24. Thor A, Moore D, Edgerton S, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of the p53 tumor suppressor gene protein is an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
25. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369-71.
26. Andersen T, Holm R, Nesland J, Heimdal KR, Ottestad L, Borresen AL. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993;68:540-8.
27. Rubio MP, von Deimling A, Yandell D, Wiestler UD, Gusella JF, Louis DN. Accumulation of wild-type p53 protein in human astrocytomas. Cancer Res 1993;53:3465-7.